Boston Scientific has reported positive clinical data from a trial, demonstrating the long-term safety of bronchial thermoplasty in patients treated with the company’s Alair bronchial thermoplasty system.

Developed by Asthmatx, the Alair system delivers thermal energy to the airway wall in a precise and controlled manner to reduce excessive airway smooth muscle, thereby reducing the frequency and severity of asthma attacks.

The trial, known as RISA, demonstrated that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with bronchial thermoplasty.

The data is consistent with recently published five-year data from the seperate AIR trial, which also demonstrated a long-term safety profile for the Alair System.

RISA trial principal investigator Dr Laviolette said that bronchial thermoplasty provides a new option for treating patients with severe asthma, and can provide proven reductions in hospital costs and visits.

"Existing evidence suggests a significant long-term benefit, and results from the RISA trial clearly confirm long-term safety,” Laviolette added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.